Abstract
Heart failure (HF) is a major public health issue with an increasing burden worldwide. The abnormalities in cardiovascular reflexes are responsible for the sympathetic hyperactivity in HF. Interrupting the activated sympathetic nervous system with β-blockers is a promising approach to alter the natural course of HF. Carvedilol is a third-generation β-blocker that offers not only non-selective β- and α1-adrenoreceptor antagonism properties, but also multiple cardioprotective effects that are beneficial in HF management. Carvedilol is a well studied β-blocker with numerous reports of efficacy across all stages of HF, as well as HF in dialysis patients. The better therapeutic efficacy and tolerability profiles of carvedilol compared with β1-selective β-blockers should make carvedilol an attractive option in the management of HF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
